MarketCap
Facebook
X
Telegram
Grifols, S.A. ROCE Ratio | GRFS
Annual ROCE Ratio Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.19 | 4.19 | 4.07 | - | 7.15 | 7.98 | 8.86 | 10.09 | -50.81 | 6.22 | 6.34 | 6.79 | 9.66 | 0.08 |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.09 | -50.81 | 2.06 |
Quarterly ROCE Ratio Grifols, S.A.
| 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.19 | 4.19 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.19 | 4.19 | 5.19 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AzurRx BioPharma, Inc.
AZRX
|
1008280076442.74 | - | 2.07 % | $ 34.4 M |  USA |
 |
Cerecor Inc.
CERC
|
-165.76 | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
-30.35 | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
-29.73 | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
-21.36 | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
-8.19 | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
-6.64 | - | - | $ 6.81 B |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
-76.77 | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
-100.1 | - | - | $ 256 M |  Canada |
 |
Neos Therapeutics, Inc.
NEOS
|
-37.85 | - | -2.54 % | $ 57.2 M | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
-90.5 | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
-92.78 | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
0.55 | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
-17318.55 | - | - | $ 1.77 B | USA |
 |
Translate Bio, Inc.
TBIO
|
-0.85 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
-22.0 | - | - | $ 1.94 B | Canada |
 |
Urovant Sciences Ltd.
UROV
|
-441.32 | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-15.64 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
-60.71 | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
-40.18 | - | -4.97 % | $ 664 M | USA |
 |
Yunhong International
ZGYH
|
-0.45 | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
-62.79 | - | -7.58 % | $ 264 M | USA |
 |
Leap Therapeutics
LPTX
|
-26.75 | - | 368.57 % | $ 41.9 M | USA |
 |
Cortexyme
CRTX
|
162.59 | - | -1.05 % | $ 67.1 M | USA |
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
163.88 | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
27.01 | - | - | $ 3.85 B | USA |
 |
ARCA biopharma
ABIO
|
-25.86 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-17.34 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
-348.87 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
14.97 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-33.44 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
99.68 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
-7787.01 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-127.7 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
21.27 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-122.58 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-123.17 | - | -5.98 % | $ 34.1 M | USA |